Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia

Arati V. Rao Department of Medicine, Divisions of Medical Oncology, Pharmacology, and Cellular Therapy, Duke University Medical Center, Durham, NC, USACorrespondence[email protected]

Islam R. Younis Department of Basic Pharmaceutical Sciences and MBR Cancer Center, West Virginia University, Morgantown, WV, USA

Gregory J. Sand Department of Medicine, Divisions of Medical Oncology, Pharmacology, and Cellular Therapy, Duke University Medical Center, Durham, NC, USA

Ivan Spasojevic Department of Medicine, Divisions of Medical Oncology, Pharmacology, and Cellular Therapy, Duke University Medical Center, Durham, NC, USA

David J. Adams Department of Medicine, Divisions of Medical Oncology, Pharmacology, and Cellular Therapy, Duke University Medical Center, Durham, NC, USA

Carlos M. Decastro Department of Medicine, Divisions of Medical Oncology, Pharmacology, and Cellular Therapy, Duke University Medical Center, Durham, NC, USA

John P. Gockerman Department of Medicine, Divisions of Medical Oncology, Pharmacology, and Cellular Therapy, Duke University Medical Center, Durham, NC, USA

Bercedis L. Peterson Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC

William P. Petros Department of Basic Pharmaceutical Sciences and MBR Cancer Center, West Virginia University, Morgantown, WV, USA

Joseph O. Moore Department of Medicine, Divisions of Medical Oncology, Pharmacology, and Cellular Therapy, Duke University Medical Center, Durham, NC, USA

David A. Rizzieri Department of Medicine, Divisions of Medical Oncology, Pharmacology, and Cellular Therapy, Duke University Medical Center, Durham, NC, USA

show all

Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date